May 24, 2020

POINT Biopharma Announces Manufacturing Leadership and Search for US manufacturing site

March  24, 2020 - Toronto - POINT Biopharma Inc. today  announced the appointment of Todd Hockemeyer as Executive Vice President  of US Manufacturing Operations. An industrial engineer, with operations  and manufacturing expertise spanning over 25 years, Hockemeyer brings  forward significant expertise in radiopharmaceutical manufacturing,  quality systems and regulatory affairs. Todd joins most recently from  Radiomedix where he led the construction and operations of a full-scale  commercial radiopharmaceutical manufacturing facility. Previously,  Hockemeyer led Zevacor’s quality and regulatory affairs team.

POINT  anticipates completing its targeted search for a US manufacturing site  in the next quarter and will be committing significant capital funding  to build a state-of-the-art, GMP pharmaceutical facility. Along with  capital investment, plans include hiring of a stable, highly educated  next generation manufacturing and operations workforce. This investment  in internal, wholly owned manufacturing capacity complements POINT  Biopharma’s announced clinical program set to begin in 2020 and  positions the Company to be an innovative leader in end to end drug  manufacturing, clinical development and patient access.

“I  am excited to join the POINT executive team and lead the site buildout  and US manufacturing operations for the Company. We look forward to  investing in US jobs and building our team,” said Todd Hockemeyer.

Joe  McCann, POINT Biopharma’s CEO adds, “We are pleased that Todd has  assumed this important leadership role. His extensive experience in  manufacturing leadership and business operations is unparalleled in the  industry and we have no doubt will prove invaluable as POINT takes  immediate steps to establish our manufacturing presence in the US.”